F
Fortive Corporation
FTV · Technology
Q4 FY2025
Earning ended Dec 31, 2025Report generated Mar 10, 2026
Compliance Infrastructure in Industrial Clothing: The Market Hasn't Noticed
Most investors price Fortive as a diversified industrial compounder subject to capex cycles — they're missing that Gordian, Intelex, and Accruent function as compliance-grade systems of record where the switching cost is a regulatory audit event, not a vendor preference, which means the IOS segment should trade at a meaningful premium to anything in the industrial hardware peer group.
Flowly Score
Apr 16 Close
+48%$59.65
Fair Value
$88.00
67
Strongat $59.65
Business Strength7/10
The regulatory embedding thesis is real — Intelex, Gordian, and Censis create compliance-anchored switching costs that make these software assets stickier than their industrial parentage suggests. The lingering predecessor-as-Advisor governance structure and hardware commoditization pressure at the low end keep this from scoring higher.
Financial Resilience7/10
Operating cash flow has consistently and substantially exceeded net income for five straight years — the amortization-heavy income statement chronically understates cash reality, not the reverse. Leverage at 2.6x EBITDA is manageable, though the aggressive balance sheet drawdown for 2025 buybacks leaves less cushion heading into any cyclical softness.
Growth & Trajectory6/10
The revenue decline is a scalpel, not a wound — portfolio surgery disguising what is actually a cleaner, higher-margin business underneath. But 2-3% core growth guided for 2026 is not a compounding machine story; it's a steady-state franchise where earnings growth depends on buybacks and margin expansion doing the heavy lifting that organic volume is not.
Valuation7/10at $56.35
The FCF yield on the post-divestiture business tells a more interesting story than the headline P/E — the market appears to be applying an industrial conglomerate multiple to a business whose IOS segment deserves enterprise software pricing, and that gap between perception and reality is where the opportunity lives. Even the pessimistic scenario barely dips below current price, suggesting the downside is reasonably bounded.
Risk6/10
No existential threats, but three concrete ones deserve active monitoring: AI-native EHS competitors lowering the switching cost calculus for products that are entrenched but not beloved, hospital mega-system consolidation giving centralized procurement leverage over ASP and Censis, and China's structural retreat removing a growth lever without replacement. The succession ambiguity with a predecessor formally on the leadership roster is an underappreciated governance overhang.
The investment case rests on a valuation gap created by category confusion. The post-divestiture Fortive is effectively two businesses: a precision instruments franchise with genuine brand loyalty and calibration-standard stickiness, and an enterprise software portfolio where customers can't easily leave because their EHS audit trail, facility cost data, and surgical instrument traceability records live inside the platform. The market sees an industrial company with a software hobby; the more accurate description is a software compliance infrastructure business that still makes very good multimeters. That distinction matters enormously for terminal value. The trajectory is one of deliberate simplification — each divestiture strips out a lower-multiple business and concentrates the remaining cash flow in stickier, higher-margin assets. The Fortive Business System provides a genuine operating engine that acquirees get plugged into, evidenced by five consecutive years of gross margin expansion. The EPS growth story for 2026 is partly buyback arithmetic, but the underlying margin expansion is structural and real, not financial engineering. The open question is whether the IOS platform businesses can demonstrate genuine cross-sell velocity between Gordian, Accruent, and Intelex — unified facility intelligence platform versus three separate sales motions is the difference between a software compounder and a portfolio of decent standalone assets. The single biggest risk is not cyclicality but AI-native disruption of the compliance software stack. Intelex and Accruent are entrenched because migration is painful, not because customers love the product — and that is a fundamentally weaker moat than one built on genuine product superiority. If an AI-first competitor builds a genuinely better EHS workflow at lower total cost of ownership, the pain of staying can start to exceed the pain of leaving, and the switching cost thesis unravels from the bottom of the market upward before showing up in retention metrics.